SciencemachineA British AI Startup has fully accelerated biotech data analysis with autonomous agents, raised € 2.9 million pre-marks funding for sales and pharma partnerships, especially to support product development and appointment.
The round was led by Juniper and strategic aspirations, led by Revent and Nucleus Capital.
“Our goal is to help make the bioforma groundbreaking discoveries faster and cheaper,” Say Lorenzo SaniCEO and co-founder of Sciencemachin. “Our AI agent works twenty -four hours, analyzing the data of research from the lab to the clinic, raw data turns into breakthroughs in a few hours instead of a few months
Established in 2025, Sciencemachine AI is creating agents that convert biotech and pharma companies to analyze and discover how data analyzes. The product of its flag, SamAlways act as on-AI bioinformatics, scientists help to find insight at their research faster, more accurately and at low cost.
The Organization’s autonomous AI agent, Sam24/7 acts as a bioinformatician, automatically automatically for biotech and pharma companies by automatically automatically pipelines and enables quickly scientific discoveries.
With only two teams, and automatic work with AI, the sciencemacine team has demanded that their size be over 100 times, launching a completely autonomous AI agent that has already been used by biotech customers. Both have been distributed, except for marketing expenses or sales teams ”Many big players have not yet achieved“: Production-level AI automation that reduces costs and accelerates scientific discoveries.
Rebecca brillMain, Revent, Wise: “Sciencemachine is an impressive example that we have seen about performing pure. They have made a product with just two that provides measured value not just technically the best-class, but also to the customers. They are perfectly located to disrupt one of the world’s largest and most important markets.“
Sciencemachine has solved a problem that slowly slows the biomedical progress: Life Sciences research teams face unprotected floods of complex biological information from labs and clinics, but adequate data struggles to appoint scientists, a key role for them. In parallel, domain experts often lack time or training to carry out sophisticated biotech analysis. As a result, the company says that many discoveries are delayed, or completely missed.
You have an agent Sam This gap shows to close: it integrates directly with the existing database and lab workflies, then processes continuous experimental data to find patterns, insights and potential breakthroughs without any manual intervention. In fact, SAM provides the same output of researchers that usually need a full team of data scientists, accelerate their work significantly.
Sam Data operates everything from cleaning to search analysis to visualization, uninterruptedly and autonomously unlocks quick research cycles and reduces the cost of invention.
Early customers report a third of the time, in a fraction of the price and they can earn themselves higher than they can achieve themselves.
MaximilianGeneral partner, nucleus says: “We believe that agent architecture will become a dominant interface for scientific software. Sciencemachine ideally extends access to complex bioinformatics for wet-lab scientists dramatically expand and speed up the recurrence cycle and eventually enhances the addressable market.”
One month after the launch, Sciencemachine already has multiple contracts and fast growing pipelines does not spend one percent on marketing.
Funds will support product development and appointment, especially in sales and pharma partners.
Sciencemachine is planning to extend its reaching its reach from Biotech Startups to larger companies – where ACVs are high and more scaleable, flexible data automation is greater.
Michael LucianiGeneral partner, Juniper says: “Ben and Lorenzo have the fastest pace of implementing any team we met in this place, the brief understanding of how to go on the market and scale and the most well -thought -out product we have tried is the key to success in this case.”
[publish_date
